They got bounced out of Alexion. Now David Hallal and Vikas Sinha are back with $150M and a focus on cell and gene therapies
David Hallal and Vikas Sinha got bounced out of their jobs as CEO and CFO of Alexion the hard way more than 2 years ago, dismissed after failing to maintain the confidence of the board as a probe into the company’s sketchy sales and billing practices triggered a top-to-bottom overhaul of the management and the operations — with a move to Boston.
But it didn’t end their biotech careers. Not by a long shot.
“I spent more than a decade at Alexion building one of the most successful biotechs in the world,” says Hallal. And the best way to handle the situation at the end, the persistently upbeat biotech exec says, was to channel the emotion into new endeavors while “looking forward.”
Basic subscription required
Unlock this story instantly and join 55,000+ biopharma pros reading Endpoints daily — and it's free.